Research programme: small molecules therapeutics - METiS Pharmaceuticals
Latest Information Update: 27 Jun 2025
At a glance
- Originator METiS Pharmaceuticals
- Class Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Lung disorders; Neurodegenerative disorders
Most Recent Events
- 26 Jun 2025 Small molecules therapeutics - METiS Pharmaceuticals is available for licensing as of 26 Jun 2025. https://www.metispharma.com/en/about
- 26 Jun 2025 Preclinical trials in Cancer in China (unspecified route)
- 26 Jun 2025 Preclinical trials in Lung disorders in China (unspecified route)